Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Exelixis Building A Pipeline Out Of A Product, Unveils Cabozantinib Activity Across Tumor Types At ASCO

Executive Summary

Exelixis Inc. is set to file the first NDA for its dual MET/VEGF2 inhibitor cabozantinib by the end of the year, but as that project winds down, plans for a suite of new indications are in the works as the company tries to leverage its asset as fully as possible.

You may also be interested in...

Momentum In Prostate Cancer Therapy Moves Up To First-Line CRPC

The most recent events in the fast-evolving castration-resistant prostate cancer field illustrate how the major advances in therapy for patients who failed chemotherapy are now spreading to the larger population of CRPC patients receiving first-line therapy for metastatic disease. The upcoming year should see Phase III results from candidates ranging from a kinase inhibitor to an antisense agent.

Ovarian Cancer: Roche's Avastin And Others Show Potential, But Also Raise The "Value" Question

Roche/Genentech rolled out yet more data on Avastin (bevacizumab) in ovarian cancer at the American Society of Clinical Oncology meeting in Chicago June 3-7, but other companies also had promising results for new therapies that might help break the historical 24-month survival barrier for the difficult cancer.

Exelixis' Lead-In Trial Design Evaluates Cabozantinib Disease Activity Against Multiple Cancers At 12 Weeks

Novel adaptive randomized discontinuation design tested cabozantinib in nine tumor types, isolated best opportunities faster than traditional randomization.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts